{"id":"NCT02329223","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2014-12-31","resultsPosted":"2016-09-20","lastUpdate":"2016-09-21"},"enrollment":218,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Uriticaria"],"interventions":[{"type":"BIOLOGICAL","name":"Omalizumab","otherNames":["Xolair"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Omalizumab 300 mg","type":"EXPERIMENTAL"},{"label":"Omalizumab 150 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This was a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment of adolescent and adult participants 12 - 75 years who received the diagnosis of refractory chronic spontaneous uriticaria and who remained symptomatic despite standard-dosed non-sedating H1 antihistamine treatment.","primaryOutcome":{"measure":"Change From Baseline in the Weekly Itch Severity Score at Week 12","timeFrame":"Baseline to Week 12","effectByArm":[{"arm":"Omalizumab 300 mg","deltaMin":-10.22,"sd":0.571},{"arm":"Omalizumab 150 mg","deltaMin":-8.8,"sd":0.591},{"arm":"Placebo","deltaMin":-6.51,"sd":0.581}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"0.006"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":39,"countries":["Japan","South Korea"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":73},"commonTop":["NASOPHARYNGITIS","HEADACHE","ECZEMA","URTICARIA","PHARYNGITIS"]}}